Literature DB >> 6155334

Mucin model for group B type III streptococcal infection in mice.

D O Fleming.   

Abstract

An experimental murine infection was established by the intraperitoneal injection of a log-phase culture of a laboratory reference strain of Streptococcus agalactiae, Lancefield group B, type III (strain SS620), suspended in sterile hog gastric mucin. The enhancement of streptococcal virulence was measured by a significantly increased mortality in outbred ICR Swiss mice. An inbred C57BL6 strain of mice was resistant to the mucin-bacterial combination. Mucin, treated with Desferal to chelate the iron, did not lose the capacity to enhance the virulence of group B, type III streptococci in ICR Swiss mice. Iron-dextran was not a suitable substitute for mucin and failed to enhance the virulence of group B, type III streptococci. The results of these studies indicate that iron is not the resistance-lowering factor in this group B, type III streptococci-mucin model.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155334      PMCID: PMC550786          DOI: 10.1128/iai.27.2.449-454.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  EXPERIMENTAL MENINGOCOCCAL INFECTION IN MICE.

Authors:  C P Miller
Journal:  Science       Date:  1933-10-13       Impact factor: 47.728

2.  Microcapsule of type III strains of group B Streptococcus: production and morphology.

Authors:  C J Baker; D L Kasper
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

Review 3.  Group B streptococcal infection in humans.

Authors:  H W Wilkinson
Journal:  Annu Rev Microbiol       Date:  1978       Impact factor: 15.500

Review 4.  Iron and infection.

Authors:  E D Weinberg
Journal:  Microbiol Rev       Date:  1978-03

5.  Reduced bactericidal capacity of polymorphs in iron deficiency.

Authors:  R K Chandra
Journal:  Arch Dis Child       Date:  1973-11       Impact factor: 3.791

6.  An etiologic shift in infantile osteomyelitis: the emergence of the group B streptococcus.

Authors:  M S Edwards; C J Baker; M L Wagner; L H Taber; F F Barrett
Journal:  J Pediatr       Date:  1978-10       Impact factor: 4.406

7.  Adult mice as a model for early onset group B streptococcal disease.

Authors:  D E Wennerstrom; R W Schutt
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

8.  Type-specific antigens of group B type Ic streptococci.

Authors:  H W Wilkinson; R G Eagon
Journal:  Infect Immun       Date:  1971-11       Impact factor: 3.441

9.  Mouse protection test for group B Streptococcus type III.

Authors:  R S Baltimore; D L Kasper; J Vecchitto
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  7 in total

1.  O-Acetylation of sialic acid on Group B Streptococcus inhibits neutrophil suppression and virulence.

Authors:  Shannon Weiman; Satoshi Uchiyama; Feng-Ying C Lin; Donald Chaffin; Ajit Varki; Victor Nizet; Amanda L Lewis
Journal:  Biochem J       Date:  2010-05-13       Impact factor: 3.857

2.  Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus.

Authors:  C J Baker; M S Edwards; B J Webb; D L Kasper
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

3.  Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection.

Authors:  Greg Harris; Bruce E Holbein; Hongyan Zhou; H Howard Xu; Wangxue Chen
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

4.  Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis.

Authors:  L Tissi; P Marconi; P Mosci; L Merletti; P Cornacchione; E Rosati; S Recchia; C von Hunolstein; G Orefici
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

5.  Mouse protection assay for group B streptococcus type III.

Authors:  D O Fleming
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

6.  Antibody to group B Streptococcus type III in human sera measured by a mouse protection test.

Authors:  R S Baltimore; C J Baker; D L Kasper
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

7.  Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

Authors:  M L Egan; D G Pritchard; H C Dillon; B M Gray
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.